Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia-Reference-Cited by-同舟云学术

Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia

Published:2020-07-10 Issue:13 Volume:4 Page:3136-3140
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Kasbekar Monica¹,Nardi Valentina²,Dal Cin Paola³,Brunner Andrew M.⁴,Burke Meghan⁴,Chen Yi-Bin⁵,Connolly Christine⁴,Fathi Amir T.⁴,Foster Julia⁴,Macrae Molly⁴,McAfee Steven L.⁵,McGregor Kristin⁶,Narayan Rupa⁴,Ramos Aura Y.⁴,Som Tina T.⁴,Vartanian Meghan⁴,Friedman Robb S.⁶,Benhadji Karim A.⁷,Hobbs Gabriela S.⁴^ORCID

Affiliation:

1. Department of Medicine and

2. Department of Pathology, Massachusetts General Hospital, Boston, MA;

3. Department of Pathology, Brigham and Women’s Hospital, Boston, MA;

4. Massachusetts General Hospital Cancer Center, Boston, MA;

5. Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA;

6. Cancer Center, Newton-Wellesley Hospital, Newton, MA; and

7. Taiho Oncology, Princeton, NJ

Abstract

Key Points A novel PCM1-FGFR1 gene rearrangement was identified in a patient with a myeloid neoplasm with eosinophilia. Futibatinib, an oral selective small molecule inhibitor of FGFR1-4, resulted in a durable complete hematologic and cytogenetic remission.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/4/13/3136/1748293/advancesadv2020002308.pdf

Reference23 articles.

1. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [published correction appears in Blood. 2016;128(3):462-463];Arber;Blood,2016

2. Myeloid neoplasms with eosinophilia;Reiter;Blood,2017

3. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1;Macdonald;Acta Haematol,2002

4. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1;Bain;Haematologica,2010

5. Anchored multiplex PCR for targeted next-generation sequencing;Zheng;Nat Med,2014

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals;Current Hematologic Malignancy Reports;2024-07-22

2. Section E6.1–6.6 of the American College of Medical Genetics and Genomics (ACMG) Technical Laboratory Standards: Cytogenomic studies of acquired chromosomal abnormalities in neoplastic blood, bone marrow, and lymph nodes;Genetics in Medicine;2024-04

3. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management;American Journal of Hematology;2024-03-29

4. NUP214 fusion genes in acute leukemias: genetic characterization of rare cases;Frontiers in Oncology;2024-03-20

5. Hematological Neoplasms with Eosinophilia;Cancers;2024-01-12